COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection

Kacper Lechowicz, Sylwester Drożdżal, Filip Machaj, Jakub Rosik, Bartosz Szostak, Małgorzata Zegan-Barańska, Jowita Biernawska, Wojciech Dabrowski, Iwona Rotter, Katarzyna Kotfis, Kacper Lechowicz, Sylwester Drożdżal, Filip Machaj, Jakub Rosik, Bartosz Szostak, Małgorzata Zegan-Barańska, Jowita Biernawska, Wojciech Dabrowski, Iwona Rotter, Katarzyna Kotfis

Abstract

In December 2019, a novel coronavirus, SARS-CoV-2, appeared, causing a wide range of symptoms, mainly respiratory infection. In March 2020, the World Health Organization (WHO) declared Coronavirus Disease 2019 (COVID-19) a pandemic, therefore the efforts of scientists around the world are focused on finding the right treatment and vaccine for the novel disease. COVID-19 has spread rapidly over several months, affecting patients across all age groups and geographic areas. The disease has a diverse course; patients may range from asymptomatic to those with respiratory failure, complicated by acute respiratory distress syndrome (ARDS). One possible complication of pulmonary involvement in COVID-19 is pulmonary fibrosis, which leads to chronic breathing difficulties, long-term disability and affects patients' quality of life. There are no specific mechanisms that lead to this phenomenon in COVID-19, but some information arises from previous severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS) epidemics. The aim of this narrative review is to present the possible causes and pathophysiology of pulmonary fibrosis associated with COVID-19 based on the mechanisms of the immune response, to suggest possible ways of prevention and treatment.

Keywords: ARDS; COVID-19; SARI; SARS-CoV-2; coronavirus; pathophysiology; pneumonia; pulmonary fibrosis; treatment.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The pathogenesis of pulmonary fibrosis.
Figure 2
Figure 2
Antiviral treatment in COVID-19.
Figure 3
Figure 3
Suggested treatment options for pulmonary fibrosis in COVID-19.

References

    1. Wuhan Municipal Health Commission Report of Clustering Pneumonia of Unknown Etiology in Wuhan City. [(accessed on 18 June 2020)];2019 Wuhan. Available online: .
    1. World Health Organization . General’s Opening Remarks at the Media Briefing on COVID-19-18 March 2020. World Health Organization; Geneva, Switzerland: 2020.
    1. World Health Organization . Coronavirus Disease (COVID-2019) Situation Reports. World Health Organization; Geneva, Switzerland: 2020. Coronavirus Disease (COVID-2019) Situation Report—101.
    1. World Health Organization Coronavirus Disease (COVID-2019) Situation Reports. [(accessed on 13 April 2020)]; Available online: .
    1. Chan J.F., Yuan S., Kok K.H., To K.K., Chu H., Yang J., Xing F., Liu J., Yip C.C., Poon R.W., et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet. 2020;395:514–523. doi: 10.1016/S0140-6736(20)30154-9.
    1. Gu J., Han B., Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology. 2020 doi: 10.1053/j.gastro.2020.02.054.
    1. Kotfis K., Skonieczna-Zydecka K. COVID-19: Gastrointestinal symptoms and potential sources of 2019-nCoV transmission. Anaesthesiol. Intensive Ther. 2020 doi: 10.5114/ait.2020.93867.
    1. Xia J., Tong J., Liu M., Shen Y., Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J. Med. Virol. 2020 doi: 10.1002/jmv.25725.
    1. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Ren R., Leung K.S.M., Lau E.H.Y., Wong J.Y., et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N. Engl. J. Med. 2020;382:1199–1207. doi: 10.1056/NEJMoa2001316.
    1. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 doi: 10.1001/jama.2020.1585.
    1. World Health Organization . Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease Is Suspected: Interim Guidance v 1.2, 13 March 2020. World Health Organization; Geneva, Switzerland: 2020.
    1. Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 doi: 10.1001/jama.2020.2648.
    1. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7.
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Kotfis K., Williams Roberson S., Wilson J.E., Dabrowski W., Pun B.T., Ely E.W. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. Crit. Care (Lond. Engl.) 2020;24:176. doi: 10.1186/s13054-020-02882-x.
    1. Kotfis K., Williams Roberson S., Wilson J.E., Pun B.T., Ely E.W. COVID-19: What do we need to know about ICU Delirium during SARS-CoV-2 pandemic? Anaesthesiol. Intensive Ther. 2020 in press.
    1. Kukla W., Skonieczna-Żydecka K., Kotfis K., Maciejewska D., Łoniewski I., Lara L.L., Pazgan-Simon M., Stachowska E., Kaczmarczyk M., Kaulaouzidis A., et al. Coronavirus disease 2019 (Covid-19), MERS and SARS with concomittant liver injury—Systematic review of the existing literature. J. Clin. Med. 2020 in press.
    1. Lippi G., Plebani M., Henry B.M. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin. Chim. Acta Int. J. Clin. Chem. 2020;506:145–148. doi: 10.1016/j.cca.2020.03.022.
    1. Wang J., Wang B.J., Yang J.C., Wang M.Y., Chen C., Luo G.X., He W.F. Advances in the research of mechanism of pulmonary fibrosis induced by Corona Virus Disease 2019 and the corresponding therapeutic measures. Zhonghua Shao Shang Za Zhi Zhonghua Shaoshang Zazhi Chin. J. Burn. 2020;36:E006. doi: 10.3760/cma.j.cn501120-20200307-00132.
    1. Pan F., Ye T., Sun P., Gui S., Liang B., Li L., Zheng D., Wang J., Hesketh R.L., Yang L., et al. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. Radiology. 2020:200370. doi: 10.1148/radiol.2020200370.
    1. Pan Y., Guan H., Zhou S., Wang Y., Li Q., Zhu T., Hu Q., Xia L. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): A study of 63 patients in Wuhan, China. Eur. Radiol. 2020 doi: 10.1007/s00330-020-06731-x.
    1. Shi H., Han X., Jiang N., Cao Y., Alwalid O., Gu J., Fan Y., Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet. Infect. Dis. 2020;20:425–434. doi: 10.1016/S1473-3099(20)30086-4.
    1. Grasselli G., Zangrillo A., Zanella A., Antonelli M., Cabrini L., Castelli A., Cereda D., Coluccello A., Foti G., Fumagalli R., et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 doi: 10.1001/jama.2020.5394.
    1. Wong C.K., Lam C.W.K., Wu A.K.L., Ip W.K., Lee N.L.S., Chan I.H.S., Lit L.C.W., Hui D.S.C., Chan M.H.M., Chung S.S.C., et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 2004;136:95–103. doi: 10.1111/j.1365-2249.2004.02415.x.
    1. Lau S.K.P., Lau C.C.Y., Chan K.H., Li C.P.Y., Chen H., Jin D.Y., Chan J.F.W., Woo P.C.Y., Yuen K.Y. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: Implications for pathogenesis and treatment. J Gen. Virol. 2013;94:2679–2690. doi: 10.1099/vir.0.055533-0.
    1. Hui D.S.C., Zumla A. Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features. Infect. Dis. Clin. North Am. 2019;33:869–889. doi: 10.1016/j.idc.2019.07.001.
    1. Nassar M.S., Bakhrebah M.A., Meo S.A., Alsuabeyl M.S., Zaher W.A. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: Epidemiology, pathogenesis and clinical characteristics. Eur. Rev. Med. Pharm. Sci. 2018;22:4956–4961. doi: 10.26355/eurrev_201808_15635.
    1. Venkataraman T., Coleman C.M., Frieman M.B. Overactive Epidermal Growth Factor Receptor Signaling Leads to Increased Fibrosis after Severe Acute Respiratory Syndrome Coronavirus Infection. J. Virol. 2017;91 doi: 10.1128/JVI.00182-17.
    1. Song Z., Xu Y., Bao L., Zhang L., Yu P., Qu Y., Zhu H., Zhao W., Han Y., Qin C. From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses. 2019;11:59. doi: 10.3390/v11010059.
    1. Zhang P., Li J., Liu H., Han N., Ju J., Kou Y., Chen L., Jiang M., Pan F., Zheng Y., et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: A 15-year follow-up from a prospective cohort study. Bone Res. 2020;8:8. doi: 10.1038/s41413-020-0084-5.
    1. Lai R.Q., Feng X.D., Gu Y.Y., Lai H.W., Liu F., Tian Y., Wang Z.C., Zhang W., Chen G.Q., Yang C.H., et al. Pathological changes of lungs in patients with severity acute respiratory syndrome. Zhonghua Bing Li Xue Za Zhi. 2004;33:354–357.
    1. Venkataraman T., Frieman M.B. The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis. Antivir. Res. 2017;143:142–150. doi: 10.1016/j.antiviral.2017.03.022.
    1. Gralinski L.E., Bankhead A., 3rd, Jeng S., Menachery V.D., Proll S., Belisle S.E., Matzke M., Webb-Robertson B.J., Luna M.L., Shukla A.K., et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio. 2013;4 doi: 10.1128/mBio.00271-13.
    1. Chiang C.H., Shih J.F., Su W.J., Perng R.P. Eight-month prospective study of 14 patients with hospital-acquired severe acute respiratory syndrome. Mayo Clin. Proc. 2004;79:1372–1379. doi: 10.4065/79.11.1372.
    1. Zuo W., Zhao X., Chen Y.-G. SARS Coronavirus and Lung Fibrosis. In: Lal S.K., editor. Molecular Biology of the SARS-Coronavirus. Springer; Berlin/Heidelberg, Germany: 2010. pp. 247–258.
    1. Xie L.X., Liu Y.N., Hao F.Y., Dong J., Cao L., Xu H.M., Tian Q., Fan B.X., Li Y.P., Ma L., et al. Prognostic analysis of lung function and chest X-ray changes of 258 patients with severe acute respiratory syndrome in rehabilitation after discharge. Zhonghua Jie He He Hu Xi Za Zhi. 2004;27:147–150.
    1. Xie L., Liu Y., Fan B., Xiao Y., Tian Q., Chen L., Zhao H., Chen W. Dynamic changes of serum SARS-coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge. Respir. Res. 2005;6:5. doi: 10.1186/1465-9921-6-5.
    1. Hwang D.M., Chamberlain D.W., Poutanen S.M., Low D.E., Asa S.L., Butany J. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod. Pathol. 2005;18:1–10. doi: 10.1038/modpathol.3800247.
    1. Das K.M., Lee E.Y., Singh R., Enani M.A., Al Dossari K., Van Gorkom K., Larsson S.G., Langer R.D. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J. Radiol. Imaging. 2017;27:342–349. doi: 10.4103/ijri.IJRI_469_16.
    1. van den Brand J.M., Smits S.L., Haagmans B.L. Pathogenesis of Middle East respiratory syndrome coronavirus. J. Pathol. 2015;235:175–184. doi: 10.1002/path.4458.
    1. Xu X., Chen P., Wang J., Feng J., Zhou H., Li X., Zhong W., Hao P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci. China Life Sci. 2020;63:457–460. doi: 10.1007/s11427-020-1637-5.
    1. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi: 10.1038/nature02145.
    1. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003;348:1953–1966. doi: 10.1056/NEJMoa030781.
    1. Zhang H., Penninger J.M., Li Y., Zhong N., Slutsky A.S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020 doi: 10.1007/s00134-020-05985-9.
    1. Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 doi: 10.1016/j.cell.2020.02.052.
    1. Hoffmann M., Kleine-Weber H., Krüger N., Müller M., Drosten C., Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020 doi: 10.1101/2020.01.31.929042.
    1. Sungnak W., Huang N., Bécavin C., Berg M., Network H. SARS-CoV-2 Entry Genes Are Most Highly Expressed in Nasal Goblet and Ciliated Cells within Human Airways. arXiv. 20202003.06122
    1. Sime P.J., O’Reilly K.M. Fibrosis of the lung and other tissues: New concepts in pathogenesis and treatment. Clin. Immunol. (Orlandofla) 2001;99:308–319. doi: 10.1006/clim.2001.5008.
    1. Razzaque M.S., Taguchi T. Pulmonary fibrosis: Cellular and molecular events. Pathol. Int. 2003;53:133–145. doi: 10.1046/j.1440-1827.2003.01446.x.
    1. Naik P.K., Moore B.B. Viral infection and aging as cofactors for the development of pulmonary fibrosis. Expert Rev. Respir. Med. 2010;4:759–771. doi: 10.1586/ers.10.73.
    1. Otoupalova E., Smith S., Cheng G., Thannickal V.J. Oxidative Stress in Pulmonary Fibrosis. Compr. Physiol. 2020;10:509–547. doi: 10.1002/cphy.c190017.
    1. Gonzalez-Gonzalez F.J., Chandel N.S., Jain M., Budinger G.R.S. Reactive oxygen species as signaling molecules in the development of lung fibrosis. Transl. Res. J. Lab. Clin. Med. 2017;190:61–68. doi: 10.1016/j.trsl.2017.09.005.
    1. Grimminger F., Günther A., Vancheri C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur. Respir. J. 2015;45:1426. doi: 10.1183/09031936.00149614.
    1. Nile S.H., Nile A., Qiu J., Li L., Jia X., Kai G. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020 doi: 10.1016/j.cytogfr.2020.05.002.
    1. Yuki K., Fujiogi M., Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin. Immunol. 2020;215:108427. doi: 10.1016/j.clim.2020.108427.
    1. Xiong Y., Liu Y., Cao L., Wang D., Guo M., Jiang A., Guo D., Hu W., Yang J., Tang Z., et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg. Microbes Infect. 2020;9:761–770. doi: 10.1080/22221751.2020.1747363.
    1. Zemans R.L., Colgan S.P., Downey G.P. Transepithelial Migration of Neutrophils. Am. J. Respir. Cell Mol. Biol. 2009;40:519–535. doi: 10.1165/rcmb.2008-0348TR.
    1. George P.M., Wells A.U., Jenkins R.G. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir. Med. 2020 doi: 10.1016/S2213-2600(20)30225-3.
    1. Pittet J.-F., Griffiths M.J.D., Geiser T., Kaminski N., Dalton S.L., Huang X., Brown L.A.S., Gotwals P.J., Koteliansky V.E., Matthay M.A., et al. TGF-β is a critical mediator of acute lung injury. J. Clin. Investig. 2001;107:1537–1544. doi: 10.1172/JCI11963.
    1. Hamada N., Kuwano K., Yamada M., Hagimoto N., Hiasa K., Egashira K., Nakashima N., Maeyama T., Yoshimi M., Nakanishi Y. Anti-Vascular Endothelial Growth Factor Gene Therapy Attenuates Lung Injury and Fibrosis in Mice. J. Immunol. 2005;175:1224. doi: 10.4049/jimmunol.175.2.1224.
    1. Meduri G.U., Headley S., Kohler G., Stentz F., Tolley E., Umberger R., Leeper K. Persistent Elevation of Inflammatory Cytokines Predicts a Poor Outcome in ARDS: Plasma IL-1β and IL-6 Levels Are Consistent and Efficient Predictors of Outcome Over Time. Chest. 1995;107:1062–1073. doi: 10.1378/chest.107.4.1062.
    1. Li X., Ma X. Acute respiratory failure in COVID-19: Is it “typical” ARDS? Crit. Care. 2020;24:198. doi: 10.1186/s13054-020-02911-9.
    1. Guan W.-J., Ni Z.-y., Hu Y., Liang W.-h., Ou C.-q., He J.-x., Liu L., Shan H., Lei C.-l., Hui D.S.C., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032.
    1. Ai T., Yang Z., Hou H., Zhan C., Chen C., Lv W., Tao Q., Sun Z., Xia L. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. 2020:200642. doi: 10.1148/radiol.2020200642.
    1. Ranucci M., Ballotta A., Di Dedda U., Bayshnikova E., Dei Poli M., Resta M., Falco M., Albano G., Menicanti L. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J. Thromb. Haemost. 2020 doi: 10.1111/jth.14854.
    1. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
    1. Stockman L.J., Bellamy R., Garner P. SARS: Systematic review of treatment effects. PLoS Med. 2006;3:e343. doi: 10.1371/journal.pmed.0030343.
    1. Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475. doi: 10.1016/S0140-6736(20)30317-2.
    1. Arabi Y.M., Mandourah Y., Al-Hameed F., Sindi A.A., Almekhlafi G.A., Hussein M.A., Jose J., Pinto R., Al-Omari A., Kharaba A., et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am. J. Respir. Crit. Care Med. 2018;197:757–767. doi: 10.1164/rccm.201706-1172OC.
    1. Ni Y.-N., Chen G., Sun J., Liang B.-M., Liang Z.-A. The effect of corticosteroids on mortality of patients with influenza pneumonia: A systematic review and meta-analysis. Crit. Care (Lond. Engl.) 2019;23:99. doi: 10.1186/s13054-019-2395-8.
    1. Wu C., Chen X., Cai Y., Xia J.a., Zhou X., Xu S., Huang H., Zhang L., Zhou X., Du C., et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern. Med. 2020 doi: 10.1001/jamainternmed.2020.0994.
    1. Lee N., Allen Chan K.C., Hui D.S., Ng E.K.O., Wu A., Chiu R.W.K., Wong V.W.S., Chan P.K.S., Wong K.T., Wong E., et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J. Clin. Virol. 2004;31:304–309. doi: 10.1016/j.jcv.2004.07.006.
    1. World Health Organization . Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (nCoV) Infection is Suspected. World Health Organization; Geneva, Switzerland: 2020.
    1. Barut F., Ozacmak V.H., Turan I., Sayan-Ozacmak H., Aktunc E. Reduction of Acute Lung Injury by Administration of Spironolactone After Intestinal Ischemia and Reperfusion in Rats. Clin. Investig. Med Med. 2016;39:E15–E24. doi: 10.25011/cim.v39i1.26326.
    1. Yavas G., Yavas C., Celik E., Sen E., Ata O., Afsar R.E. The impact of spironolactone on the lung injury induced by concomitant trastuzumab and thoracic radiotherapy. Int. J. Radiat. Res. 2019;17 doi: 10.1016/j.jtho.2018.08.997.
    1. Zannad F., Alla F., Dousset B., Perez A., Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000;102:2700–2706. doi: 10.1161/01.CIR.102.22.2700.
    1. Lieber G.B., Fernandez X., Mingo G.G., Jia Y., Caniga M., Gil M.A., Keshwani S., Woodhouse J.D., Cicmil M., Moy L.Y., et al. Mineralocorticoid receptor antagonists attenuate pulmonary inflammation and bleomycin-evoked fibrosis in rodent models. Eur. J. Pharmacol. 2013;718:290–298. doi: 10.1016/j.ejphar.2013.08.019.
    1. Atalay C., Dogan N., Aykan S., Gundogdu C., Keles M.S. The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats. Singap. Med. J. 2010;51:501–505.
    1. Ji W.-J., Ma Y.-Q., Zhou X., Zhang Y.-D., Lu R.-Y., Guo Z.-Z., Sun H.-Y., Hu D.-C., Yang G.-H., Li Y.-M., et al. Spironolactone attenuates bleomycin-induced pulmonary injury partially via modulating mononuclear phagocyte phenotype switching in circulating and alveolar compartments. PLoS ONE. 2013;8:e81090. doi: 10.1371/journal.pone.0081090.
    1. Maleszka P., Kruszewski J. Comparative evaluation of inhaling a single dose of furosemide or spironolactone on bronchial hyperreactivity of patients with atopic bronchial asthma. Pol. Tyg. Lek. (Warsaw Poland 1960) 1994;49:415–418.
    1. Brower R.G., Matthay M.A., Morris A., Schoenfeld D., Thompson B.T., Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N. Engl. J. Med. 2000;342:1301–1308. doi: 10.1056/NEJM200005043421801.
    1. Ware L.B. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin. Respir. Crit. Care Med. 2006;27:337–349. doi: 10.1055/s-2006-948288.
    1. Tian S., Hu W., Niu L., Liu H., Xu H., Xiao S.-Y. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer. 2020 doi: 10.1016/j.jtho.2020.02.010.
    1. Yang Y., Tang H. Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumonia. Cell. Mol. Immunol. 2016;13:432–442. doi: 10.1038/cmi.2016.1.
    1. MacLaren R., Stringer K.A. Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome. Pharmacotherapy. 2007;27:860–873. doi: 10.1592/phco.27.6.860.
    1. Ware L.B., Camerer E., Welty-Wolf K., Schultz M.J., Matthay M.A. Bench to bedside: Targeting coagulation and fibrinolysis in acute lung injury. Am. J. Physiology. Lung Cell. Mol. Physiol. 2006;291:L307–L311. doi: 10.1152/ajplung.00157.2006.
    1. Hardaway R.M., Harke H., Tyroch A.H., Williams C.H., Vazquez Y., Krause G.F. Treatment of severe acute respiratory distress syndrome: A final report on a phase I study. Am. Surg. 2001;67:377–382.
    1. Stringer K.A., Hybertson B.M., Cho O.J., Cohen Z., Repine J.E. Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak. Free Radic. Biol. Med. 1998;25:184–188. doi: 10.1016/S0891-5849(98)00047-1.
    1. Moore H.B., Barrett C.D., Moore E.E., McIntyre R.C., Moore P.K., Talmor D.S., Moore F.A., Yaffe M.B. Is There a Role for Tissue Plasminogen Activator as a Novel Treatment for Refractory COVID-19 Associated Acute Respiratory Distress Syndrome? J. Trauma Acute Care Surg. 2020;88:713–714. doi: 10.1097/TA.0000000000002694.
    1. Wardlaw J.M., Murray V., Berge E., del Zoppo G.J. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst. Rev. 2014:CD000213. doi: 10.1002/14651858.CD000213.pub3.
    1. Kim Y., Liu H., Galasiti Kankanamalage A.C., Weerasekara S., Hua D.H., Groutas W.C., Chang K.O., Pedersen N.C. Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. PLoS Pathog. 2016;12:e1005531. doi: 10.1371/journal.ppat.1005531.
    1. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV) Biosci. Trends. 2020;14:69–71. doi: 10.5582/bst.2020.01020.
    1. Channappanavar R., Fett C., Mack M., Ten Eyck P.P., Meyerholz D.K., Perlman S. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. J. Immunol. 2017;198:4046–4053. doi: 10.4049/jimmunol.1601896.
    1. Zumla A., Chan J.F., Azhar E.I., Hui D.S., Yuen K.Y. Coronaviruses—Drug discovery and therapeutic options. Nat. Rev. Drug Discov. 2016;15:327–347. doi: 10.1038/nrd.2015.37.
    1. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0.
    1. Biot C., Daher W., Chavain N., Fandeur T., Khalife J., Dive D., De Clercq E. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J. Med. Chem. 2006;49:2845–2849. doi: 10.1021/jm0601856.
    1. Baron S.A., Devaux C., Colson P., Raoult D., Rolain J.-M. Teicoplanin: An alternative drug for the treatment of coronavirus COVID-19? Int. J. Antimicrob. Agents. 2020:105944. doi: 10.1016/j.ijantimicag.2020.105944.
    1. Arabi Y.M., Alothman A., Balkhy H.H., Al-Dawood A., AlJohani S., Al Harbi S., Kojan S., Al Jeraisy M., Deeb A.M., Assiri A.M., et al. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): Study protocol for a randomized controlled trial. Trials. 2018;19:81. doi: 10.1186/s13063-017-2427-0.
    1. Yuen K.S., Ye Z.W., Fung S.Y., Chan C.P., Jin D.Y. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci. 2020;10:40. doi: 10.1186/s13578-020-00404-4.
    1. de Wit E., Feldmann F., Cronin J., Jordan R., Okumura A., Thomas T., Scott D., Cihlar T., Feldmann H. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc. Natl. Acad. Sci. USA. 2020 doi: 10.1073/pnas.1922083117.
    1. Sheahan T.P., Sims A.C., Graham R.L., Menachery V.D., Gralinski L.E., Case J.B., Leist S.R., Pyrc K., Feng J.Y., Trantcheva I., et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 2017;9 doi: 10.1126/scitranslmed.aal3653.
    1. Grein J., Ohmagari N., Shin D., Diaz G., Asperges E., Castagna A., Feldt T., Green G., Green M.L., Lescure F.-X., et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2007016.
    1. Agostini M.L., Andres E.L., Sims A.C., Graham R.L., Sheahan T.P., Lu X., Smith E.C., Case J.B., Feng J.Y., Jordan R., et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018;9 doi: 10.1128/mBio.00221-18.
    1. Chu C.M., Cheng V.C., Hung I.F., Wong M.M., Chan K.H., Chan K.S., Kao R.Y., Poon L.L., Wong C.L., Guan Y., et al. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax. 2004;59:252–256. doi: 10.1136/thorax.2003.012658.
    1. Chan J.F., Yao Y., Yeung M.L., Deng W., Bao L., Jia L., Li F., Xiao C., Gao H., Yu P., et al. Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J. Infect Dis. 2015;212:1904–1913. doi: 10.1093/infdis/jiv392.
    1. Dhama K., Sharun K., Tiwari R., Dadar M., Malik Y.S., Singh K.P., Chaicumpa W. COVID-19, an emerging coronavirus infection: Advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum. Vaccines Immunother. 2020:1–7. doi: 10.1080/21645515.2020.1735227.
    1. Coleman C.M., Sisk J.M., Mingo R.M., Nelson E.A., White J.M., Frieman M.B. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J. Virol. 2016;90:8924–8933. doi: 10.1128/JVI.01429-16.
    1. Dong L., Hu S., Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19) Drug Discov. 2020;14:58–60. doi: 10.5582/ddt.2020.01012.
    1. Lu C.-C., Chen M.-Y., Lee W.-S., Chang Y.-L. Potential therapeutic agents against COVID-19: What we know so far. J. Chin. Med. Assoc. 2020;83 doi: 10.1097/JCMA.0000000000000318.
    1. Cai Q., Yang M., Liu D., Chen J., Shu D., Xia J., Liao X., Gu Y., Cai Q., Yang Y., et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020 doi: 10.1016/j.eng.2020.03.007.
    1. Irie K., Nakagawa A., Fujita H., Tamura R., Eto M., Ikesue H., Muroi N., Tomii K., Hashida T. Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19. Clin. Transl. Sci. 2020 doi: 10.1111/cts.12827.
    1. Caly L., Druce J.D., Catton M.G., Jans D.A., Wagstaff K.M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir. Res. 2020;178:104787. doi: 10.1016/j.antiviral.2020.104787.
    1. Channel News Asia . China Approves Use of Roche Arthritis Drug for COVID-19 Patients. Mediacorp; Singapore: 2020.
    1. Harrison C. Coronavirus puts drug repurposing on the fast track. Nat. Biotechnol. 2020;38:379–381. doi: 10.1038/d41587-020-00003-1.
    1. Xu X., Han M., Li T., Sun W., Wang D., Fu B., Zhou Y., Zheng X., Yang Y., Li X., et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl. Acad. Sci. USA. 2020;117:10970–10975. doi: 10.1073/pnas.2005615117.
    1. Chen L., Xiong J., Bao L., Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis. 2020;20:398–400. doi: 10.1016/S1473-3099(20)30141-9.
    1. Kraft C.S., Hewlett A.L., Koepsell S., Winkler A.M., Kratochvil C.J., Larson L., Varkey J.B., Mehta A.K., Lyon G.M., 3rd, Friedman-Moraco R.J., et al. The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2015;61:496–502. doi: 10.1093/cid/civ334.
    1. Cheng Y., Wong R., Soo Y.O.Y., Wong W.S., Lee C.K., Ng M.H.L., Chan P., Wong K.C., Leung C.B., Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 2005;24:44–46. doi: 10.1007/s10096-004-1271-9.
    1. Mair-Jenkins J., Saavedra-Campos M., Baillie J.K., Cleary P., Khaw F.-M., Lim W.S., Makki S., Rooney K.D., Nguyen-Van-Tam J.S., Beck C.R. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. J. Infect. Dis. 2015;211:80–90. doi: 10.1093/infdis/jiu396.
    1. Shen C., Wang Z., Zhao F., Yang Y., Li J., Yuan J., Wang F., Li D., Yang M., Xing L., et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020;323:1582–1589. doi: 10.1001/jama.2020.4783.
    1. Matsuyama S., Kawase M., Nao N., Shirato K., Ujike M., Kamitani W., Shimojima M., Fukushi S. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv. 2020 doi: 10.1101/2020.03.11.987016.
    1. Jeon S., Ko M., Lee J., Choi I., Byun S.Y., Park S., Shum D., Kim S. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob. Agents Chemother. 2020 doi: 10.1128/AAC.00819-20.
    1. Becher B., Tugues S., Greter M. GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation. Immunity. 2016;45:963–973. doi: 10.1016/j.immuni.2016.10.026.
    1. Zheng Y., Huang Z., Ying G., Zhang X., Ye W., Hu Z., Hu C., Wei H., Zeng Y., Chi Y., et al. Study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting other factors besides uncontrolled inflammation contributed to multi-organ injury. medRxiv. 2020 doi: 10.2139/ssrn.3555267.
    1. Rivera-Ortega P., Hayton C., Blaikley J., Leonard C., Chaudhuri N. Nintedanib in the management of idiopathic pulmonary fibrosis: Clinical trial evidence and real-world experience. Ther. Adv. Respir. Dis. 2018;12:1753466618800618. doi: 10.1177/1753466618800618.
    1. Richeldi L., Varone F., Bergna M., de Andrade J., Falk J., Hallowell R., Jouneau S., Kondoh Y., Morrow L., Randerath W., et al. Pharmacological management of progressive-fibrosing interstitial lung diseases: A review of the current evidence. Eur. Respir. Rev. 2018;27 doi: 10.1183/16000617.0074-2018.
    1. OncoArendi Therapeutics (OAT) Drug Candidate OATD-01 May Find Use in Treatment of Pulmonary Fibrosis in Patients Who Have Survived a New Coronavirus Infection (COVID-19) OncoArendi Therapeutics (OAT); Warsaw, Poland: 2020.
    1. Dymek B., Sklepkiewicz P., Mlacki M., Zagozdzon A., Koralewski R., Mazur M., Paplinska-Goryca M., Nejman-Gryz P., Proboszcz M., Gorska K., et al. CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): Anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis. Eur. Respir. J. 2018;52:OA5361. doi: 10.1183/13993003.congress-2018.OA5361.
    1. Liu T., Liu X., Li W. Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy. Oncotarget. 2016;7:40800–40815. doi: 10.18632/oncotarget.8315.
    1. Bhagya N., Chandrashekar K.R. Tetrandrine—A molecule of wide bioactivity. Phytochemistry. 2016;125:5–13. doi: 10.1016/j.phytochem.2016.02.005.
    1. Liu C., Hu Y., Xu L., Liu C., Liu P. Effect of Fuzheng Huayu formula and its actions against liver fibrosis. Chin. Med. 2009;4:12. doi: 10.1186/1749-8546-4-12.
    1. Song Y., Zhao J., Wang S., Huang H., Hong J., Zuo J., Huo S. The efficacy of Chinese patent medicine combined with entecavir for the treatment of chronic HBV-related liver fibrosis or cirrhosis: Protocol for a systematic review and meta-analysis of randomized controlled trials or prospective cohort studies. Medicine (Baltimore) 2019;98:e15732. doi: 10.1097/MD.0000000000015732.
    1. Berebichez-Fridman R., Montero-Olvera P.R. Sources and Clinical Applications of Mesenchymal Stem Cells: State-of-the-art review. Sultan Qaboos Univ. Med. J. 2018;18:e264–e277. doi: 10.18295/squmj.2018.18.03.002.
    1. Azargoon A., Negahdari B. Lung regeneration using amniotic fluid mesenchymal stem cells. Artif. Cells Nanomed. Biotechnol. 2018;46:447–451. doi: 10.1080/21691401.2017.1337023.
    1. Carraro G., Perin L., Sedrakyan S., Giuliani S., Tiozzo C., Lee J., Turcatel G., De Langhe S.P., Driscoll B., Bellusci S., et al. Human amniotic fluid stem cells can integrate and differentiate into epithelial lung lineages. Stem Cells. 2008;26:2902–2911. doi: 10.1634/stemcells.2008-0090.
    1. Thom S.R. Hyperbaric oxygen: Its mechanisms and efficacy. Plast Reconstr. Surg. 2011;127(Suppl. 1):131s–141s. doi: 10.1097/PRS.0b013e3181fbe2bf.
    1. Aricigil M., Dundar M.A., Yucel A., Arbag H., Arslan A., Aktan M., Findik S., Kilinc I. Anti-inflammatory effects of hyperbaric oxygen on irradiated laryngeal tissues. Braz. J. Otorhinolaryngol. 2018;84:206–211. doi: 10.1016/j.bjorl.2017.02.001.
    1. Solaimanzadeh I. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19) Cureus. 2020;12:e7343. doi: 10.7759/cureus.7343.
    1. Luks A., Freer L., Grissom C., McIntosh S.E., Schoene R.B., Swenson E., Hackett P.H. COVID-19 Lung Injury is Not High Altitude Pulmonary Edema. High Alt. Med. Biol. 2020 doi: 10.1089/ham.2020.0055.
    1. Chen J.-Y., Qiao K., Liu F., Wu B., Xu X., Jiao G.-Q., Lu R.-G., Li H.-X., Zhao J., Huang J., et al. Lung transplantation as therapeutic option in acute respiratory distress syndrome for COVID-19-related pulmonary fibrosis. Chin. Med. J. 2020 doi: 10.1097/CM9.0000000000000839.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj